Anastrozole is a potent and highly selective non-steroidal aromatase inhibitor. It inhibits the enzyme aromatase, which is responsible for converting androgens to estrogens. Anastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Anastrozole is the active ingredient of these drugs:
Italy
Ireland
Spain
Ireland
Germany
Finland
Tunisia
Tunisia
Germany
Australia
Austria
Brazil
Germany
Finland
Singapore
Singapore
Hong Kong
Italy
Brazil
Hong Kong Singapore
Brazil
Cyprus Hong Kong Singapore
Australia
Australia Austria Brazil Canada Cyprus
Singapore
Poland
Tunisia
Lithuania
Poland
Italy
Hong Kong Singapore
Italy
Italy
Italy
Cyprus
Cyprus
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):